Amazon Expands Healthcare Ecosystem with GLP-1 Weight Management Program

Amazon is positioning itself as a primary facilitator for the growing GLP-1 weight loss market by launching a comprehensive weight management program through Amazon One Medical. By treating obesity as a chronic condition, the company aims to provide a tailored, end-to-end healthcare journey for patients. The GLP-1 drug class, currently dominated by Eli Lilly and Novo Nordisk, has seen explosive growth due to its efficacy in treating both type 2 diabetes and obesity. With the total market forecast to approach $100 billion by 2030, competition is intensifying among pharmaceutical giants and diversified tech players. Amazon's new offering integrates virtual and in-person medical appointments with its existing pharmacy logistics. The program provides patients with pre-visit screening, prescriptions for latest-generation drugs such as Foundayo and oral Wegovy, and ongoing follow-up consultations. To enhance accessibility, Amazon is leveraging its delivery infrastructure to offer same-day delivery in nearly 3,000 U.S. cities. From a financial perspective, Amazon expects to generate revenue through One Medical membership fees as well as specific visit and pharmacy service charges. By bundling medical consultations with rapid fulfillment, the company is attempting to solve common patient pain points regarding drug access and prescription management, potentially increasing the lifetime value of its healthcare subscribers.